Rakuten Medical
PrivateLast Round
Series F
Jan 7, 2026
Est. Valuation
$1.2B
Total Funding Raised
$1.19B
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Rakuten Medical is a biotechnology company that develops precision-targeted cancer therapies aimed at treating solid tumors through the use of monoclonal antibody conjugates activated by light to selectively eliminate cancer cells while preserving healthy tissue.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rakuten Medical Comparables
Compare Rakuten Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ImPact Biotech | 78% | |
| Aura Biosciences | 73% | |
| Illuminate Therapeutics | 69% |
For institutional investors. Book with your work email.
Rakuten Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F | Jan 7, 2026 | ||||
| Series E | Mar 6, 2024 | ||||
| Convertible Debt | Dec 1, 2022 | ||||
| Series D | Jul 28, 2021 | ||||
| Series C Extension | Jul 31, 2019 | ||||
Series C | Dec 20, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Rakuten Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Daiwa Securities Group | Series F |
| MS&AD Insurance Group Holdings | Series F |
| NEXUS CVC Partners Corporation | Series F |
| General Catalyst | Series D |
| ABIES Capital | Series F |
| Mitsui Sumitomo Insurance | Series F |
| Mizuho Bank, Ltd. | Series E |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
New preclinical findings presented at AACR 2026 on photoimmunotherapy platform.
- Apr 21, 2026
Presented new preclinical findings at the AACR 2026 conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 22, 2026
Rakuten Medical Inc. presents long-term follow-up results from ASP-1929 photoimmunotherapy combined with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma at ESMO 2026 in Spain on Oct 23rd '26.
- attends_eventOct 22, 2026
Rakuten Medical Inc. presents long-term follow-up results from the ASP-1929-181 study at the European Society for Medical Oncology (ESMO) Congress 2026 in Spain on Oct 23rd '26.
- is_developingOct 22, 2026
Rakuten Medical Inc. is developing Alluminox platform-based photoimmunotherapy, which combines drug administration with targeted illumination using medical devices.
- promotesSep 25, 2026
Rakuten Medical Inc. promotes Hassan Danesi to chief medical officer; he previously serves as vice president, clinical development at Coherus Biosciences.
- hiresSep 9, 2026
On Sep 9th '26, Rakuten Medical Inc. appoints Christophe Weber as vice chairman, and he is expected to support the company's broader growth strategy as it expands in the United States.
For institutional investors. Book with your work email.
Rakuten Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Rakuten Medical's valuation, stock price, and market status.
Is Rakuten Medical a public or private company?
Rakuten Medical is a private company.
What is the current stock price of Rakuten Medical?
Rakuten Medical is a private company, so its shares have no public market price. Caplight tracks Rakuten Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Rakuten Medical worth (valuation)?
Rakuten Medical's valuation is estimated at $1.2B based on funding round data.
Can I buy Rakuten Medical stock?
Rakuten Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Rakuten Medical's last funding round?
Rakuten Medical's most recent funding round was Series F on January 7, 2026.
Who are the main investors in Rakuten Medical?
Key investors in Rakuten Medical include General Catalyst, Hikma Ventures.
Will Rakuten Medical IPO soon?
No public IPO plans have been announced for Rakuten Medical.
How can I track Rakuten Medical secondary market activity?
Caplight tracks bids, offers, and trades in Rakuten Medical's shares on secondary markets.